ARMOUR Residential REIT, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Scott J. Ulm
- Full Time Employees
- 20
- Sector
- Finance
- Industry
- Real estate investment trusts
- Address
- 3001 Ocean Drive Vero Beach FL United States 32963
- IPO Date
- Dec 3, 2007
- CIK
- 0001428205
- Website
- armourreit.com
- Similar Companies
- Business
- ARMOUR Residential REIT, Inc. (NYSE: ARR) is a real estate investment trust that primarily invests in and manages a leveraged portfolio of residential mortgage-backed securities (RMBS), consisting of fixed-rate, adjustable-rate and hybrid adjustable-rate securities issued or guaranteed by U.S. government-sponsored enterprises such as Fannie Mae and Freddie Mac or by the Government National Mortgage Association (Ginnie Mae); it also holds unsecured notes and bonds issued by these entities, U.S. treasuries and money market instruments. The company, founded in 2008 and headquartered in Vero Beach, Florida, operates exclusively in the United States and pursues attractive risk-adjusted returns for shareholders through active portfolio management, interest rate risk hedging with derivatives including swaps, swaptions and futures, and leverage via repurchase agreements, while distributing substantially all of its taxable income as required for REIT status. Externally managed by ARMOUR Capital Management LP, ARMOUR Residential REIT targets income-seeking investors with its high monthly dividend policy, recently set at $0.24 per common share for December 2025; recent strategic changes include multiple reverse stock splits in 2017, 2020 and 2023 to maintain NYSE compliance, an expansion of its at-the-market equity offering program in 2024 with the addition of Janney Montgomery Scott LLC as a sales agent and an increase in authorized common shares from 90 million to 125 million, a public offering of 18.5 million common shares announced in August 2025 to fund additional MBS acquisitions with an underwriter option for 2.775 million more shares, and ongoing portfolio adjustments through interest rate volatility including a reported Agency MBS portfolio of approximately $12.4 billion as of late 2024 alongside distributable earnings of $75.3 million in Q3 2025.
Company News
Armour Residential REIT (ARR) Q3 Earnings Lag Estimates
ARMOUR Residential REIT, Inc. Announces Q3 Results And September 30, 2026 Financial Position
ARMOUR Residential REIT, Inc. Announces Margaret Field Karr Has Joined as Strategic Investor Relations Advisor
ARMOUR Residential REIT, Inc. Announces November 2026 Dividend Rate Per Common Share
ARMOUR Residential REIT, Inc. Third Quarter 2026 Webcast Scheduled for October 22, 2026
Buy 7 October Dividend Power Dogs If You Dare
Rezolve AI Targets $500M ARR as Agentic Commerce Platform Scales
ARMOUR Residential REIT (NYSE:ARR) Sets New 1-Year Low – Should You Sell?
ARMOUR Residential REIT, Inc. Confirms October 2026 Common Share and Q4 2026 Series C Preferred Share Dividends
ARMOUR Residential REIT, Inc. (NYSE:ARR) Receives Consensus Recommendation of “Hold” from Analysts
Cowboy State Mine Study Strengthens Foundation for Domestic U.S. Rare Earth Supply
ARMOUR Residential REIT, Inc. Announces Guidance for October 2026 Dividend Rate Per Common Share
Can Guidewire Software Maintain Its Robust ARR Growth Momentum?
Are Investors Undervaluing ARMOUR Residential REIT (ARR) Right Now?
These Huge Mortgage REIT Yields Are Really a Bet on Interest Rates
SpaceX CFO: New Compute Deal Puts Company Closer to $100B ARR Goal
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Could SpaceX Really 5X Its Revenue in a Single Year? Surprisingly, the Math Actually Works Out (if Elon Musk Can Do This 1 Big Thing).
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
6 Ultra-High-Yield Names Where Coverage Is Cracking